Contraline is a clinical-stage biotechnology company focused on innovation in male reproductive health. The company is advancing both hormonal and non-hormonal approaches to expand contraceptive options for men and couples globally.
Following its recently completed Series B financing, Contraline is entering a pivotal stage of growth as it advances toward late-stage clinical development, regulatory milestones, expanded manufacturing, and future product launch.
The company's owner for pharmaceutical Chemistry, Manufacturing & Controls (CMC), responsible for defining strategy and driving execution from Phase 3 readiness through regulatory approval and commercial launch manufacturing.